Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa

Table 3

Characteristic	(a) Hazard ratio	95% CI	P value	(b) Hazard ratio	95% CI	P value
Age	1.00	0.96–1.05	0.844	1.00	0.96–1.04	0.985
Male	1.30	0.65–2.60	0.464	1.68	0.84–3.39	0.142
Baseline CD4 cell count	0.99	0.97–1.00	0.028	0.99	0.98–1.00	0.059
Log₁₀ Viral load (copies/ml)	0.94	0.50–1.78	0.848	0.85	0.45–1.61	0.612
WHO stage 4	1.91	0.98–3.73	0.059	1.62	0.83–3.16	0.162
Tuberculosis (all cases)	1.13	0.59–2.17	0.710	0.95	0.49–1.86	0.883
Log suPAR concentration ng/ml	-	-	-	9.96	2.78–35.7	<0.001

Cox proportional hazards model showing the association between baseline characteristics of patients (n = 293) and subsequent death before starting antiretroviral treatment (ART) or during the first 16 weeks ART. The first model (a) shows associations with baseline patient characteristics whereas the second model (b) also includes plasma log suPAR concentration.

ISSN: 1471-2334